| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$6,305 ) |
| | 2025 | 2022 | PROTEOVISTA LLC | 510 CHARMANY DR STE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 000 | 3 | NIH | 10/9/2024 | $0 |
| | 2025 | 2020 | PROTEOVISTA LLC | 510 CHARMANY DR STE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 001 | 2 | NIH | 12/4/2024 | -$6,305 |
|
| Issue Date FY: 2023 ( Subtotal = $376,800 ) |
| | 2023 | 2023 | PROTEOVISTA LLC | 510 CHARMANY DR | MADISON | WI | 53719-1266 | DANE | USA | R43HG012745 | Development of GenomeBuild as a Universal Method to Synthesize Genomes | 000 | 1 | NIH | 3/6/2023 | $376,800 |
| | 2023 | 2022 | PROTEOVISTA LLC | 510 CHARMANY DR | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 000 | 3 | NIH | 8/25/2023 | $0 |
| | 2023 | 2019 | PROTEOVISTA LLC | 510 CHARMANY DR | MADISON | WI | 53719-1266 | DANE | USA | R43CA236167 | Development of the High Throughput APT-SNAP Platform for Rapid Identification ofNuclease-Resistant RNA Aptamers against p53 Missense Mutations | 000 | 1 | NIH | 7/25/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $110,028 ) |
| | 2022 | 2022 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 000 | 3 | NIH | 5/6/2022 | $110,028 |
| | 2022 | 2018 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R43CA232913 | Site-Specific Incorporation of Phosphorylation Modifications on the SNAP-Tide High Density Peptide Array | 000 | 1 | NIH | 4/13/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 000 | 2 | NIH | 8/6/2021 | $0 |
| | 2021 | 2019 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R43CA236167 | Development of the High Throughput APT-SNAP Platform for Rapid Identification ofNuclease-Resistant RNA Aptamers against p53 Missense Mutations | 000 | 1 | NIH | 8/27/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $297,460 ) |
| | 2020 | 2020 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 000 | 2 | NIH | 4/28/2020 | $168,410 |
| | 2020 | 2020 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 001 | 2 | NIH | 9/14/2020 | $129,050 |
| | 2020 | 2018 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R43CA232913 | Site-Specific Incorporation of Phosphorylation Modifications on the SNAP-Tide High Density Peptide Array | 000 | 1 | NIH | 9/4/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $392,937 ) |
| | 2019 | 2019 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA229069 | SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants | 000 | 1 | NIH | 4/30/2019 | $168,410 |
| | 2019 | 2019 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R43CA236167 | Development of the High Throughput APT-SNAP Platform for Rapid Identification ofNuclease-Resistant RNA Aptamers against p53 Missense Mutations | 000 | 1 | NIH | 9/5/2019 | $224,527 |
|
| Issue Date FY: 2018 ( Subtotal = $222,678 ) |
| | 2018 | 2018 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R43CA232913 | Site-Specific Incorporation of Phosphorylation Modifications on the SNAP-Tide High Density Peptide Array | 000 | 1 | NIH | 8/6/2018 | $222,678 |
| | 2018 | 2016 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R43HL118893 | Aptamer-Based Detection of Cardiac Biomarker Glycosylation States Using APT-SNAP | 000 | 2 | NIH | 8/10/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2015 | PROTEOVISTA LLC | 510 CHARMANY DRIVE, SUITE 57 | MADISON | WI | 53719-1266 | DANE | USA | R21CA182335 | High Density Peptide Arrays for Cancer-Related Post-Translational Modifications | 000 | 3 | NIH | 9/19/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $326,050 ) |
| | 2016 | 2016 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R43HL118893 | Aptamer-Based Detection of Cardiac Biomarker Glycosylation States Using APT-SNAP | 000 | 2 | NIH | 5/7/2016 | $326,050 |
|
| Issue Date FY: 2015 ( Subtotal = $107,112 ) |
| | 2015 | 2015 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R21CA182335 | High Density Peptide Arrays for Cancer-Related Post-Translational Modifications | 000 | 3 | NIH | 8/6/2015 | $107,112 |
| | 2015 | 2014 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R43HL118893 | Aptamer-Based Detection of Cardiac Biomarker Glycosylation States Using APT-SNAP | 000 | 1 | NIH | 8/15/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $525,146 ) |
| | 2014 | 2014 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R43HL118893 | Aptamer-Based Detection of Cardiac Biomarker Glycosylation States Using APT-SNAP | 000 | 1 | NIH | 8/18/2014 | $317,350 |
| | 2014 | 2014 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R21CA182335 | High Density Peptide Arrays for Cancer-Related Post-Translational Modifications | 001 | 2 | NIH | 8/6/2014 | $207,796 |
| | 2014 | 2013 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R21CA182335 | High Density Peptide Arrays for Cancer-Related Post-Translational Modifications | 000 | 1 | NIH | 1/6/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $208,123 ) |
| | 2013 | 2013 | ILLUMAVISTA BIOSCIENCES LLC | 505 SOUTH ROSA ROAD | MADISON | WI | 53719 | DANE | USA | R21CA182335 | High Density Peptide Arrays for Cancer-Related Post-Translational Modifications | 000 | 1 | NIH | 9/20/2013 | $208,123 |
| | 2013 | 2013 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R21CA182335 | High Density Peptide Arrays for Cancer-Related Post-Translational Modifications | 001 | 1 | NIH | 1/6/2014 | $0 |
| | 2013 | 2011 | PROTEOVISTA LLC | 510 CHARMANY DRIVE | MADISON | WI | 53719 | DANE | USA | R43CA159655 | SCREENING OF FOXA1-ER-DNA DISRUPTORS FOR DEVELOPMENT OF BREAST CANCER THERAPEUTIC | 000 | 1 | NIH | 8/29/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $144,658 ) |
| | 2012 | 2012 | ILLUMAVISTA BIOSCIENCES LLC | 505 SOUTH ROSA ROAD | MADISON | WI | 53719 | DANE | USA | R43CA163405 | HIGH THROUGHPUT METHOD TO ASSESS SNP FUNCTIONALITY IN PROSTATE CANCER | 000 | 2 | NIH | 9/14/2012 | $144,658 |
|
| Issue Date FY: 2011 ( Subtotal = $368,168 ) |
| | 2011 | 2011 | ILLUMAVISTA BIOSCIENCES LLC | 505 SOUTH ROSA ROAD | MADISON | WI | 53719 | DANE | USA | R43CA159655 | SCREENING OF FOXA1-ER-DNA DISRUPTORS FOR DEVELOPMENT OF BREAST CANCER THERAPEUTIC | 000 | 1 | NIH | 9/16/2011 | $218,168 |
| | 2011 | 2011 | ILLUMAVISTA BIOSCIENCES LLC | 505 SOUTH ROSA ROAD | MADISON | WI | 53719 | DANE | USA | R43CA163405 | HIGH THROUGHPUT METHOD TO ASSESS SNP FUNCTIONALITY IN PROSTATE CANCER | 000 | 1 | NIH | 9/21/2011 | $150,000 |
|
|
